Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.73 |
| ▸ | RXRB | P28702 | 17/20 | 0.73 |
| ▸ | RXRG | P48443 | 17/20 | 0.73 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049097 | 0.85 | RXRA (1.00) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL20306006 | 0.84 | RXRA (0.55) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL17049060 | 0.82 | RXRA (0.78) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL5179730 | 0.75 | RXRA (0.83) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL17049098 | 0.74 | RXRA (1.00) | RXRARXRBRXRGPPARGRARA | |
| SCHEMBL5178703 | 0.73 | RXRA (0.65) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL20411364 | 0.72 | RXRA (0.77) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL17049100 | 0.72 | RXRA (1.00) | RXRARXRBRXRGPPARGRARA | |
| SCHEMBL17053971 | 0.71 | RXRA (0.76) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL5179608 | 0.71 | RXRA (0.76) | RXRARXRBRXRGPPARGNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | RXRA 674/4885RXRB 644/4885RXRG 545/4885 |
| US-10005741-B2 | Therapeutic compounds | IAPP, PARK7, NLN | RXRA 674/4885RXRB 644/4885RXRG 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.